-
1 Comment
Eagle Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 1.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.0.
Eagle Pharmaceuticals, Inc's total revenue rose by 3.4% to $50M since the same quarter in the previous year.
Its net income has increased by 701.7% to $8M since the same quarter in the previous year.
Finally, its free cash flow grew by 688.1% to $20M since the same quarter in the previous year.
Based on the above factors, Eagle Pharmaceuticals, Inc gets an overall score of 4/5.
| Exchange | F |
|---|---|
| CurrencyCode | EUR |
| ISIN | None |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Beta | 0.52 |
|---|---|
| Market Cap | 23M |
| PE Ratio | 2.26 |
| Target Price | 48.5 |
| Dividend Yield | None |
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1E6.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
